This is a summary of the European public assessment report (EPAR) for Ruconest. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ruconest.
Therapeutic Indication
### Therapeutic indication Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency.
Therapeutic Area (MeSH)
ATC Code
B06AC04
ATC Item
conestat alfa
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| recombinant human C1-inhibitor | N/A | Conestat alfa |
| Recombinant human C1-inhibitor | N/A | Conestat alfa |
EMA Name
Ruconest
Medicine Name
Ruconest
Aliases
N/A
